{"schema_version":"secwatch.filing_event.v1","accession":"0000882095-24-000003","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2024-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.124864+00:00","generated_at":"2026-06-06T08:49:10.828980+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Gilead Q4 revenue $7.1B (-4% YoY); FY23 non-GAAP EPS $6.72; guides FY24 product sales $27.1-27.5B","bullets":["Q4 2023 GAAP EPS $1.14 (down from $1.30); non-GAAP EPS $1.72 (up from $1.67).","Full-year 2023 product sales $26.9B, flat YoY; HIV sales up 6% to $18.2B; Biktarvy up 14% to $11.8B.","Oncology sales up 37% for full year; Cell Therapy $1.9B (+28%); Trodelvy $1.1B (+56%).","Veklury sales fell 44% to $2.2B in FY23; Q4 Veklury $720M (-28% YoY).","FY24 guidance: product sales $27.1-27.5B, Veklury ~$1.3B, GAAP EPS $5.15-5.55, non-GAAP EPS $6.85-7.25."],"urls":{"canonical":"https://secwatch.observer/filing/0000882095-24-000003","json":"https://secwatch.observer/filing/0000882095-24-000003.json","markdown":"https://secwatch.observer/filing/0000882095-24-000003.md","text":"https://secwatch.observer/filing/0000882095-24-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000003/0000882095-24-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000003/gild-20240206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T08:49:10.828980+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"22bc3ebb4fb9ebd1d89dbb608d347936cea98fa6","claim":"GILEAD SCIENCES, INC. reported financial results for the quarter and year ended December 31, 2023.","evidence_excerpt":"On February 6, 2024 , Gilead Sciences, Inc., a Delaware corporation (\"Gilead\"), issued a press release announcing its financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000003/0000882095-24-000003-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}